This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The health outcomes assessed from the published studies were used as model inputs in the decision analysis.
For intensive glycaemic control, the outcomes assessed were the initial level of glycosylated haemoglobin (HbA1c), annual rate of change of HbA1c before treatment, treatment effect on HbA1c, annual rate of change of HbA1c after treatment, maximum level of HbA1c with and without treatment, and various hazard rates. The hazard rates for normal to microalbuminuria, microalbuminuria to clinical nephropathy, normal to neuropathy, and normal to photocoagulation, were assessed.
For intensive hypertension control, the outcomes assessed were risk reduction for CHD and stroke, and the hazard rates for normal to microalbuminuria, microalbuminuria to clinical nephropathy, and normal to photocoagulation.
For reduction in serum cholesterol level, the analysis assessed only the risk reduction of CHD for patients with or without CHD.
The health utility values associated with specific health states were also assessed.
Study designs and other criteria for inclusion in the review
Not stated. The authors only reported that one of the primary studies used in the analysis, the UKPDS, was a randomised controlled trial. However, the authors did refer to a technical report for more details (copy available from the authors).
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness evidence used in the decision model was mainly derived from 10 primary studies. Other studies were also used to derive effectiveness data.
Methods of combining primary studies
Investigation of differences between primary studies
Not stated. For intensive glycaemic control:
Results of the review
the initial level of HbA1c was 6.8%;
the annual rate of change of HbA1c before treatment was 0.2%;
the treatment effect on HbA1c was -2% with conventional treatment and -2.9% with intensive treatment;
the annual rate of change of HbA1c after treatment was 0.2%;
the maximum level of HbA1c was 12% without treatment, 11% with conventional treatment, and 9 with intensive treatment;
the hazard rates were 2.62 for normal to microalbuminuria, 1.08 for microalbuminuria to clinical nephropathy, 1.67 for normal to neuropathy, and 2.74 for normal to photocoagulation.
For intensive hypertension control:
the risk reduction was 13% with moderate intervention relative to no treatment, 0% (or 21%) with intensive intervention relative to moderate intervention for CHD, 17% with moderate intervention relative to no treatment, and 44% with intensive intervention relative to moderate intervention for stroke;
with moderate intervention, the hazard rates were 0.05584 for normal to microalbuminuria, 0.15050 for microalbuminuria to clinical nephropathy, and 0.01660 for normal to photocoagulation; and with intensive intervention, the hazard rates were 0.03773 for normal to microalbuminuria, 0.12810 for microalbuminuria to clinical nephropathy, and 0.01020 for normal to photocoagulation.
For reduction in serum cholesterol level, the risk reduction of CHD with pravastatin was 31% for patients without CHD and 25% for those with CHD, and 0% with no treatment.
The health utility values were 0.690 for blindness, 0.610 for end-stage renal disease, 0.8 for lower extremity amputation, 0.5 for stroke, 0.880 for cardiac arrest or myocardial infarction, and 0.947 for angina.
Methods used to derive estimates of effectiveness
The authors made some assumptions to support the data used in the decision model.
Estimates of effectiveness and key assumptions
The following assumptions were made:
all patients received conventional treatment to control blood glucose levels;
in the intensive hypertension control, the intervention had no effect on the CHD transition probabilities;
in the intensive hypertension control, all patients with a history of CHD or stroke received hypertension treatment and had faster rates of progression to microalbuminuria, clinical nephropathy, and photocoagulation than normotensive patients;
in the reduction in serum cholesterol level model, patients received pravastatin for the remaining lifetime.
Measure of benefits used in the economic analysis
The main benefit measure in the economic analysis was the QALYs. A 3% discount rate was used. The remaining (undiscounted) life-years were also assessed. Both benefit measures were derived using modelling.
Synthesis of costs and benefits
The costs and QALYs were combined using an incremental cost-utility analysis. The incremental cost per QALY gained with each intervention over standard care was $41,384 for intensive glycaemic control, -$1,959 for intensive hypertension control, and $51,889 for reduction in serum cholesterol level. Intensive hypertension control was dominant (more effective and less costly than the comparison).
Age at diagnosis had a strong impact for intensive glycaemic control. The cost per QALY started at $9,614 for patients aged 25 to 34 years and reached 2.1 million for patients aged 85 to 94 years. Age at diagnosis had little effect for intensified hypertension control and some effect for reduction in serum cholesterol level, with the lowest cost per QALY for patients aged 45 to 84 years.
All interventions reduced the cumulative incidence of complications. Dropping the assumptions did not result in substantial variations in the estimated cost-effectiveness ratios. For intensive glycaemic control, the cost-effectiveness ratios were mainly affected by a reduction in the CHD risk and the exclusion of case management costs. For reduction in serum cholesterol level, the cost-effectiveness ratios were mainly affected by the elimination of extra office visits. Intensified hypertension control remained generally associated with cost?savings, with the exception of dropping the assumption of disease progression, which led to a higher cost per QALY.
